Human reproductive technologies assist parents who are having troubles in pregnancies, and infertility issues. These technologies include Assisted Reproductive Technology (ART), prognostics, contraception, and same-sex procreation. ART aids in the treatment of low fertility or infertility using artificial insemination, artificial reproduction, cloning, cytoplasmic transfer, fertility medication, hormone treatment, and others. The second most common reason for using assisted reproductive technology is infertility. IVF completely omits the fallopian tubes for treating patients with tubal factor infertility. Male factor infertility, decreased ovarian reserve, ovarian failure (with donor eggs), ovulatory dysfunction, and unexplained infertility are among other infertility etiologies that can be treated with IVF. IVF can be utilized with a gestational carrier in patients for whom pregnancy is generally contraindicated (described below) or with uterine factor infertility. IVF is also used outside of infertility settings. It can be used in patients desiring preimplantation genetic testing before conception (such as those known to be carriers of certain genetic disorders), fertility preservation, such as prior to gonadotoxic therapy, or in patients desiring to delay childbearing. These women can opt to freeze their eggs or embryos if they are in a stable relationship. The high prevalence of maternal mortality, increasing population and increasing focus on family planning is expected to boost the global human reproductive technologies market over the forecast period.
Market Dynamics
The high prevalence of maternal mortality and increasing population had assisted the key players to focus on various growth strategies for the product launch as well as acquisitions, which will lead to the growth of global human reproductive technologies market over the forecast period. For instance, in May 2022, Perrigo Company plc., a provider of Consumer Self-Care Products, announced that it completed the acquisition of HRA Pharma, a global independent pharmaceutical company that engineers and commercializes drugs in the women's health and endocrinology segments. for US$ 1.9 billion based on current exchange rates, in cash, accelerating its position as a global consumer self-care company.
Key features of the study:
Detailed Segmentation:
Detailed Segmentation:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients